Intas Pharmaceuticals Successfully Settles USITC Section 337 Investigation
- Sterne, Kessler, Goldstein & Fox P.L.L.C.
In March 2011, the United States International Trade Commission instituted a Section 337 investigation based upon a patent infringement complaint filed by Eli Lilly. The complaint alleged that Sterne Kessler client -- Intas Pharmaceuticals Ltd. – imported and sold within the United States a generic version of Lilly’s anti-cancer drug Gemzar, which was made by a process patented by Lilly.
On August 16, 2011, after expedited discovery was taken of all parties, Lilly and Intas entered into a successful settlement agreement that resolved all disputes in this investigation. The investigation has been terminated by the Administrative Law Judge.